The CEO transition is orderly and the clinical data update is early but directionally positive. Key catalysts to watch: ESMO presentation (Oct 23-27) for more mature CLOVER data including ORR and PFS, and ASCO GI (Jan 2027) for durability. The ctDNA comparator data vs Natera real-world cohorts is the most quantitative signal but remains preliminary with only 28 of 65 patients evaluable.
Price Chart
Executive Summary
CytoDyn appointed CFO Robert E. Hoffman as CEO effective October 20, 2026, replacing Dr. Jacob Lalezari who transitions to Head of Research and Translational Sciences. The filing also includes an investor webcast presenting preliminary ctDNA data from the Phase 2 CLOVER study in mCRC showing a median 86% ctDNA decline at week 2 (n=28) and statistically significant deeper molecular responses versus Natera real-world comparator cohorts (p=0.01, p=0.0005). The CEO transition is orderly with the founder remaining in a scientific role, while the clinical data update is early-stage and preliminary.
Key Facts
- Robert E. Hoffman appointed CEO effective October 20, 2026, replacing Dr. Jacob Lalezari who becomes Head of Research and Translational Sciences
- Hoffman's annual base salary increased to $525,000 with a 50% bonus target and grant of 2,500,000 stock options
- CLOVER Phase 2 mCRC study (N=65) showed 96/96 (100%) screened patients tested CCR5+ by IHC
- Median ctDNA decline of 86% at week 2 across 28 evaluable patients (80% in 350mg cohort, 90% in 700mg cohort)
- 38/51 (74.5%) patients with scans at Week 8 demonstrated tumor shrinkage or stable disease
- No Serious Adverse Events related to leronlimab reported
- Three patients referred for curative-intent surgery
- Statistically significant deeper molecular responses vs Natera real-world comparator cohorts (p=0.01, p=0.0005)
- Upcoming data presentations at ESMO (Oct 23-27, 2026) and ASCO GI (Jan 21-23, 2027)
- Company raised $17.5M and $16.2M in two financings during calendar 2026
Financial Impact
No revenue or earnings data reported. Two financings closed in 2026: $17.5M in Q1 and $16.2M in Q3. CEO salary set at $525,000 annually.
Risk Factors
- CLOVER data is preliminary with only 34% of subjects remaining on study as of September 2026 - outcomes may change at database lock
- Company is pre-revenue clinical-stage with no approved products and history of capital raises
- Stock trades on OTCQB (not Nasdaq) with limited liquidity
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001175680-26-000038 |
| Document: ck0001175680-ex99_2.htm | 0001175680-26-000038 |
| Document: ck0001175680-ex99_1.htm | 0001175680-26-000038 |
| Document: 0001175680-26-000038-index-headers.html | 0001175680-26-000038 |
| Document: 0001175680-26-000038-index.html | 0001175680-26-000038 |
| Document: 0001175680-26-000038.txt | 0001175680-26-000038 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.2500 $0.2500 | · 0.00% | ▼ −0.53% | $0.2400 (−4.00%) |
Oct 19, 2026 7d ago | 8-K | $0.2500 $0.2500 | · 0.00% | ▼ −0.53% | $0.2400 (−4.00%) |
Oct 8, 2026 19d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.60% | $0.2400 (−20.00%) |
Oct 5, 2026 22d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.55% | $0.2400 (−20.00%) |
Oct 5, 2026 22d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.55% | $0.2400 (−20.00%) |
Sep 25, 2026 4w ago | S-3 | $0.2200 $0.2000 | ▲ +9.09% | ▲ +8.91% | $0.2400 (−9.09%) |
Mar 5, 2026 33w ago | 8-K | $0.2400 $0.2300 | ▲ +4.17% | ▲ +2.85% | $0.2400 (+0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers